Table:
2019	2018	2017	2016	2015

(in millions, except per share amounts)

Revenue	$23,406	$30,391	$20,322	$12,399	$16,192

Gross margin	10,702	17,891	8,436	2,505	5,215

Operating income	7,376	14,994	5,868	168	2,998

Net income (loss)	6,358	14,138	5,090	(275)	2,899

Net income (loss) attributable to Micron	6,313	14,135	5,089	(276)	2,899

Diluted earnings (loss) per share	5.51	11.51	4.41	(0.27)	2.47

Cash and short-term investments	7,955	6,802	5,428	4,398	3,521

Total current assets	16,503	16,039	12,457	9,495	8,596

Property, plant, and equipment	28,240	23,672	19,431	14,686	10,554

Total assets	48,887	43,376	35,336	27,540	24,143

Total current liabilities	6,390	5,754	5,334	4,835	3,905

Long-term debt	4,541	3,777	9,872	9,154	6,252

Total Micron shareholders' equity	35,881	32,294	18,621	12,080	12,302

Noncontrolling interests in subsidiaries	889	870	849	848	937

Total equity	36,770	33,164	19,470	12,928	13,239

Answer the following question drawing on the tabular data along with the context text, respond with any necessary explanation, then provide the JSON object {"answer": ["ANSWER"], "scale": "SCALE"} as the final output (use an empty string for scale if irrelevant).

Supporting text:
ITEM 6. SELECTED FINANCIAL DATA
In December 2016, we acquired the 67% remaining interest in Inotera and began consolidating Inotera's operating results. In the periods presented above through December 2016, Inotera sold DRAM products exclusively to us through supply agreements. The cash paid for the Inotera Acquisition was funded, in part, with a term loan of 80 billion New Taiwan dollars and $986 million from the sale of 58 million shares of our common stock. See "Item 8. Financial Statements and Supplementary Data – Notes to Consolidated Financial Statements – Acquisition of Inotera."

Question: What percentage of total Micron shareholders' equity contributing to total equity in 2019?

(35,881/36,770 ) * 100, therefore {"answer": "97.58", "scale": "percent"}